Academic GI Cancer Consortium Multicenter Phase II Trial Published in The Oncologist

Academic GI Cancer Consortium Multicenter Phase II Trial Published in The Oncologist

A collaborative study from the Academic GI Cancer Consortium (AGICC) has been published in The Oncologist, reporting results from a multicenter Phase II trial evaluating FOLFOXIRI plus panitumumab as first-line therapy for patients with left-sided, RAS wild-type metastatic colorectal cancer.

The study demonstrated a 74% objective response rate, 96% disease control rate, and median progression-free survival of 17 months, with the authors reporting response and progression-free survival outcomes among the highest reported in stage IV colon cancer.

Continue reading

The Latest Research in Blood Disorders

Hematology Research

New research and treatments for blood disorders have accelerated personalized care for the millions of patients living with the effects of these often serious conditions. From improved diagnostics to precision gene therapies, new technology and approaches to treatment are improving quality of life and delivering life-saving care faster.

Continue reading

2026 Skin Cancer Facts and Statistics

New Advances in Skin Cancer Research

With skin cancer rates on the rise and the first new sunscreen ingredient approved by the FDA in twenty years coming to market in August, skin cancer prevention is a hot topic this summer.

Learn about the latest skin cancer facts and statistics and the latest advancements in research.

Continue reading

Rare Disease Research Updates

Rare Disease Research Updates

Though rare diseases affect almost 30 million Americans, research challenges and hurdles for therapeutic development persist. The U.S. Orphan Drug Act defines a rare disease as a disorder that affects fewer than 200,000 individuals. These small population sizes make the typical study requirements even more challenging. With pharmaceutical companies less inclined to invest in developing treatments for these disease areas, there is great potential for clinical advancement. Research advancements in one disease may help improve our understanding of other diseases. The FDA has encouraged the study of rare diseases and recently released draft guidance to help advance precision therapies for rare diseases.

Continue reading

New Developments in Parkinson’s Disease Research

Parkinson's Disease

With Parkinson’s disease (PD) affecting the lives of millions of people, reliable and effective diagnostics and treatments are needed to ease the burden of disease on individuals and society as a whole. With knowledge of the disease growing each year, investment in research has accelerated, offering hope to people living with challenging PD symptoms.

Continue reading

Clinical Research Updates in Traumatic Brain Injury (TBI)

TBI research updates

Traumatic Brain Injury (TBI), caused by a jolt or blow to the head, or penetrating injury, such as a gunshot wound, is a significant burden for patients and society as a whole. Certain individuals are more prone to experiencing TBIs than others, like those who participate in high-risk sports and activities, such as football, horseback riding, and motorcycling. Others with high-risk careers experience higher rates of TBI, like military servicemembers, first responders, and construction and manufacturing workers.

New research, diagnostics, and treatments are offering hope to people living with the long-term effects of TBI.

Continue reading

New Advances in Cardiovascular Disease Research and Treatment

New Advances in Cardiovascular Disease Research and Treatment

Heart disease continues to be a leading cause of death in the United States. More Americans die from Cardiovascular diseases each year, including stroke, than cancer and accidents combined, though overall, death rates are declining.

Promising new research into the causes of cardiovascular disease, as well as new therapies and approaches to research and diagnosis, have the potential to revolutionize patient care.

Continue reading

Clinical Trials and Research to Watch in 2026

Clinical Trials to Watch in 2026

In 2026 there are many exciting clinical trials on the horizon that have the potential to advance research and improve patient care. From new approaches to cancer treatment, to first-in-class treatments for cardiovascular disease and promising drugs for treating long COVID, this year we hope to see study results that indicate progress in personalized medicine and accessibility of care.

Continue reading

ASCO Gastrointestinal Cancers Symposium – January 8-10, 2026

ASCO GI Cancers Symposium logo

We are excited to attend the 2026 ASCO Gastrointestinal Cancers Symposium, held in San Francisco on January 8-10, 2026. Our semi-annual Investigator’s Meeting of the Academic GI Cancer Consortium (AGICC)​ will be held on Thursday, January 8th, bringing together AGICC researchers to discuss new developments, collaboration opportunities and potential studies for 2026. 

Continue reading